Clear Cell Renal Cell Carcinoma
Key Points
Key Points
- Kidney cancer will be diagnosed in 79,000 U.S. patients in 2022 and will account for 13,920 deaths.
- Opportunities for extended survival and even durable disease control in the metastatic setting have recently appeared as novel classes of therapeutics, reshaping the trajectory of this cancer.
- This rapid evolution has paved the way for this first set of comprehensive guidelines for treating metastatic clear cell renal cell carcinoma (ccRCC).
Diagnosis
...iagnosis...
...1.1The diagnosis of metastatic clear cell re...
Recommendation 1.2Radiographic diagnosis...
Treatment
...atment...
...2.1Select patients (see Practical Information)...
...commendation 3.1Select patients with metasta...
...Line Treatmenta Select cases (see Recommendation 3...
...ation 3.2All patients with metastatic clear cell r...
....3Patients with favorable risk disease who requir...
...mendation 3.4Select patients with met...
...ecommendation 3.5The use of high d...
...n from 2023 Rapid Recommendation Update...
...ion 3.6Treatment with IpiNivoCabo is not reco...
...ion 4.1Nivolumab or cabozantinib should be of...
...endation 4.2Patients progressing on co...
...mmendation 4.3Patients who progress af...
...mmendation 4.4For patients on immun...
...5.1For patients with low volume metastati...
...mendation 5.2For patients undergoing complete me...
....1.1Patients with symptomatic bone metastases from...
...6.1.2Patients with bone metastases from m...
...re 2. Second-Line or Greater Treatmen...
...igure 3. Metastases-Directed Treatm...
...6.1.3No recommendation regarding optimal sys...
...endation 6.2.1Patients with brain metastases f...
...n 6.2.2No recommendation regarding opt...
...n 6.3Patients with metastatic clear cell ren...
...e 4. Special Patient Su...
ASCO believes that cancer clinical tria...